Drug Search Results
More Filters [+]

Melperone

Alternative Names: melperone
Latest Update: 2024-05-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: D2 Antagonist,5-HT2A Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Austria | Belgium | Czech | Denmark | Estonia | Iceland | Ireland | Latvia | Lithuania | Portugal | Sweden | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: Lundbeck
Company Location: DENMARK G7 00000
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Melperone

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Depressive Disorder|Tic Disorders|Dementia|Psychophysiologic Disorders|Schizophrenia|Other

Phase 2: Psychotic Disorders|Parkinson's Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

TDM-VIGIL

P3

Completed

Other

2018-12-31

GAP

P3

Terminated

Depressive Disorder|Tic Disorders|Dementia|Psychophysiologic Disorders|Schizophrenia

2017-06-28

13104A

P2

Completed

Psychotic Disorders|Parkinson's Disease

2008-03-01

Recent News Events